First Citizens BancShares Inc vs Inovio Pharmaceuticals Inc — how do they compare? First Citizens BancShares Inc trades at $2,252.62 (market cap $25.04B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: First Citizens BancShares Inc is far larger — about 318.8× Inovio Pharmaceuticals Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FCNCA | INO | |
|---|---|---|
Market Cap | $25.04B | $78.55M |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $2.87 |
52-Week Low | $1.64K | $0.66 |
Dividend Yield | 0.37% | — |
Enterprise Value | — | $49.56M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →